CARLSBAD, Calif., Feb. 29 Genoptix, Inc.(Nasdaq: GXDX), today announced the pricing of 2,086,957 shares of outstandingcommon stock being offered by certain existing stockholders to the public atthe price of $25.50 per share. Genoptix, Inc. will not receive any proceedsfrom the sale. The offer is expected to close on March 5, 2008.
The offering is being made through an underwriting syndicate led by LehmanBrothers, Inc. acting as sole book-running manager. Banc of AmericaSecurities LLC and UBS Investment Bank are acting as joint lead managers withCowen and Company, LLC as co-manager. The selling stockholders have grantedthe underwriters a 30-day option to purchase up to 313,043 additional sharesof common stock.
A registration statement relating to these securities was declaredeffective by the Securities and Exchange Commission on February 28, 2008.This offering is being made by the existing stockholders solely by means ofwritten prospectus. Copies of the final prospectus relating to the offeringmay be obtained, when available, by contacting Lehman Brothers, Inc., c/oBroadridge Integrated Distribution Services, 1155 Long Island Avenue,Edgewood, NY 11717, fax: 631-254-7140, or e-mail: firstname.lastname@example.org,or at the Securities and Exchange Commission's website: http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitationof an offer to buy, nor shall there be any sale of these securities in anystate or jurisdiction in which such an offer, solicitation or sale would beunlawful prior to registration or qualification under the securities laws ofany such state or jurisdiction.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused ondelivering personalized and comprehensive diagnostic services tocommunity-based hematologists and oncologists. Genoptix is headquartered inCarlsbad, California.
This press release contains forward-looking statements that are subject torisks and uncertainties that could cause actual results to differ materiallyfrom those set forth in the forward-looking statements. Actual results maydiffer materially from those projected. Genoptix disclaims, however, anyintent or obligations to update these forward-looking statements.
SOURCE Genoptix, Inc.